Oncolytics Biotech Signs a Clinical Trial Collaboration with Merck KGaA and Pfizer

Shots:

• Oncolytics collaborates with Merck KGaA and Pfizer to co-develop Oncolytics’ pelareorep in P-II BRACELET-1 study plus paclitaxel and avelumab. The cost of P-II trial will be shared b/w Pfizer and Oncolytics. Additionally, Oncolytics may exclusively develop pelareorep with Merck and Pfizer during study and post 90 days of interim analysis in HR+/HER2- MBC
• The P-II BRACELET-1 study (BReast cAnCEr with the Oncolytic Reovirus PeLareorEp in CombinaTion with anti-PD-L1 and Paclitaxel) will involve assessing of paclitaxel as monothx and in combination with pelareorep & avelumab in three cohorts enrolling 45 patients with HR+/HER2- metastatic breast cancer
• Bavencio (avelumab) is a PD-L1 Ab that blocks the interaction of PD-L1 with PD-1 receptors and is co-developed by Merck KGaA and Pfizer. Pelareorep is an IV administered immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies
  

Click here to read full press release/ article | Ref: Oncolytics Biotech | Image: Twitter